The advent of technologies allowing whole genome sequencing (WGS) at epidemiological scales allows for the performance of genome-wide screens to identify new loci likely to be involved in antimalarial resistance as well as on the acquisition of protective immunity to malaria, including uncharacterized genes encoding products of unknown function.

In this study we propose to leverage from the Therapeutic Efficacy Study and the malaria genomic surveillance project (GenMoz) conducted in Mozambique in 2022 to assess the parasite genetic   structure   in   Mozambique   and   evaluate   the   resistance   molecular landscape   following   antimalarial   treatment   failure   with   antimalarials   which currently lack validated molecular markers of resistance.

The objectives of this study are to:

1. Evaluate enrichment in genetic changes associated with decreased susceptibility to AL and AS-PY.
2. Assess the parasite genetic structure in Mozambique.